Asset Details
Do you wish to reserve the book?
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives
Do you wish to request the book?
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives
2025
Overview
Research has shown that diabetes mellitus is not just a disorder of blood sugar, but a complex metabolic imbalance that also profoundly involves lipid metabolism. Patients with diabetes often show alterations in their lipid profile, which contribute to the risk of cardiovascular complications. The EmDia clinical trial, a randomized, placebo-controlled study, has investigated the impact of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on the plasma lipidome in patients with type 2 diabetes (T2DM). The goal was to identify molecular alterations that could explain the drug’s cardiovascular and renal benefits, which extend beyond simple glucose reduction. Using an untargeted lipidomics approach and advanced statistical techniques like sparse group LASSO regression, the study identified significant and reproducible alterations in specific lipid classes, most notably lysophosphatidylcholines (LPCs), after one and twelve weeks of treatment. These changes in the lipid profile correlated with clinical parameters such as estimated glomerular filtration rate (eGFR), uric acid, and blood pressure, suggesting that LPCs could serve as biomarkers of drug response. The discovery of LPCs as potential markers of empagliflozin’s effect opens new avenues for developing pharmacodynamic biomarkers and understanding the metabolic mechanisms of action, including the relationship between lipid metabolism and kidney health.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Benzhydryl Compounds - adverse effects
/ Benzhydryl Compounds - therapeutic use
/ Blood Glucose - drug effects
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - diagnosis
/ Diabetes Mellitus, Type 2 - drug therapy
/ Glucose
/ Glucosides - adverse effects
/ Glucosides - therapeutic use
/ Humans
/ Lipid Metabolism - drug effects
/ Lipids
/ Medicine
/ Patients
/ Principal components analysis
/ Sodium-glucose cotransporter
/ Sodium-Glucose Transporter 2 Inhibitors - adverse effects
/ Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
We currently cannot retrieve any items related to this title. Kindly check back at a later time.